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Comparison of Belatacept and Tacrolimus

Abbreviations:
aHR

Adjusted Hazard Ratio

BMI

Body Mass Index

BENEFIT

Belatacept Evaluation of Nephroprotection and Efficacy as First-line

BENEFIT-EXT

Immunosuppression Trial
Belatacept Evaluation of Nephroprotection and Efficacy as First-line
Immunosuppression Trial-EXTended criteria donors

BPAR

Biopsy Proven Acute Rejection

CI

Confidence Interval

CNI

Calcineurin Inhibitor

EBV

Epstein-Barr Virus

ECD

Extended Criteria Donor

eGFR

Estimated Glomerular Filtration Rate

FDA

Federal Drug Administration

cPRA

Calculated Panel Reactive Antibody

DM

Diabetes Mellitus

ESRD

End Stage Renal Disease
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Human Leukocyte Antigen

KTR

Kidney Transplant Recipients

LD

Lymphocyte Depleting

MDRD

Modification of Diet in Renal Disease
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HLA

NODAT

New Onset Diabetes after Transplantation

OPTN

Organ Procurement and Transplantation Network

PTLD

Post-Transplant Lymphoproliferative Disease

SCD

Standard Criteria Donors

SRTR

Scientific Registry of Transplant Recipients

SD

Standard Deviation

Abstract
The performance of belatacept in a real clinical setting has not been reported. A

retrospective cohort study was conducted using registry data comparing one-year clinical
outcomes between belatacept- and tacrolimus-treated adult kidney transplant recipients
(KTR) from 6.1.2011 through 12.1.2014. Of 50 244 total patients, 417 received
belatacept+tacrolimus, 458 received belatacept alone, and 49 369 received tacrolimus alone
at discharge. In the overall study cohort, belatacept alone was associated with a higher risk
for one-year acute rejection, with highest rates associated with non-lymphocyte depleting
(LD) induction (aHR: 2.65; 95%CI: 1.90-3.70, P<.0001). There was no significant difference
in rejection rates between belatacept+tacrolimus and tacrolimus alone. In KTR meeting
inclusion criteria for the BENEFIT-EXT trial, one-year kidney function was higher with
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belatacept+tacrolimus and belatacept alone versus tacrolimus alone groups (mean eGFR:
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65.6 vs 60.4 vs 54.3 ml/min/1.73M2, respectively, P<.001). The incidence of new onset
diabetes after transplantation was significantly lower with belatacept+tacrolimus and
belatacept alone versus tacrolimus alone (1.7% vs 2.2% vs 3.8%, respectively, P=.01).
Despite improved graft function and metabolic complications with belatacept alone, it may be
advisable to add short-term tacrolimus the first year post-transplant and consider LD
induction in high rejection risk patients, as the risk to benefit ratio allows.

Introduction
Standard maintenance immunosuppression regimens following kidney transplantation

typically include a calcineurin inhibitor (CNI), either cyclosporine or tacrolimus, combined with
mycophenolate mofetil and corticosteroids (1). CNI use over the past few decades has been
associated with a reduction in the incidence of acute rejection (AR) and improvement in short-term
allograft survival (2). However, while some clear gains have been made, improvements in long-term
allograft survival have not been commensurate with those in the short-term (3). CNI nephrotoxicity
has long been considered to be one of the numerous factors that contribute to long-term damage to
transplant kidneys, although recent evidence implicates alloimmunity as a major determinant of late
kidney allograft loss (4-6). In general, CNI withdrawal or avoidance strategies have not been very
successful at preserving long-term graft function, and to date the CNIs still remain as the
cornerstone of immunosuppression for renal transplant patients (7). However, in addition to being
nephrotoxic, CNIs are significantly correlated with higher cardiometabolic complications, including
post-transplant hypertension, diabetes, and hyperlipidemia (1). A long-term goal of the transplant
community is to find an alternative immunosuppressive agent in lieu of CNIs that is not inherently
nephrotoxic, protects adequately against alloimmunity, and does not increase cardiometabolic
complications.
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Belatacept (Nulojix ; Bristol-Myers Squibb, Princeton, NJ) is a fusion receptor protein
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(CTLA4-Ig) developed as a selective co-stimulation blocker, with two amino acid substitutions in the
CTLA4 binding domain that dramatically increase binding to CD80/CD86, resulting in effective
inhibition of T-cell activation (8). The first phase III clinical trial, Belatacept Evaluation of
Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT) was a one-year,
randomized, active-controlled, multi-center trial conducted at 100 centers worldwide that targeted
adult recipients of kidneys from living or standard criteria deceased donors (SCD) (9). The second
phase III clinical trial, Belatacept Evaluation of Nephroprotection and Efficacy as First-line
Immunosuppression Trial-EXTended criteria donors (BENEFIT-EXT), targeted adult recipients of
extended criteria deceased donor (ECD) kidneys (10). Both trials showed non-inferior composite
(patient death or graft loss) outcome and improved renal function and cardiovascular outcomes at
one year in the belatacept-treated compared with the cyclosporine-treated patients. Belatacept
patients experienced a higher yet non-inferior incidence of acute rejection episodes in the BENEFIT
trial in the lower intensity FDA-approved dosage regimen compared with the cyclosporine-treated
patients, whereas in the BENEFIT-EXT trial, the incidence of acute rejection was similar across
groups. At seven years after transplantation in the BENEFIT trial, patient and graft survival and the
mean eGFR were significantly higher with belatacept than with cyclosporine (11).
Although FDA approval for the drug was received in June 2011, the experience regarding the

utilization and outcomes of belatacept in a real clinical setting, where over 90% of renal transplant
recipients in the U.S receive a tacrolimus-based regimen, have not yet been reported (2). In this
study, the utilization pattern of belatacept in the U.S., as well as efficacy and safety outcomes
associated with its use, were examined.

This article is protected by copyright. All rights reserved.
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Study Population
A retrospective observational study based on registry data from the Scientific Registry of

Transplant Recipients (SRTR) and approved by the University of Florida Institutional Review Board
(Protocol #201400666) was conducted to compare utilization patterns and clinical outcomes
between belatacept- and tacrolimus-treated kidney transplant recipients (KTR). SRTR data, including
data on all donors, wait-listed candidates, and transplant recipients in the U.S, was collected by the
members of the Organ Procurement and Transplantation Network (OPTN). The activities of the
OPTN and SRTR contractors are administered by the Health Resources and Services Administration
of the U.S. Department of Health and Human Services. The study included solitary KTR 18 years or
older who received belatacept+tacrolimus-, belatacept- (without CNI, termed belatacept alone) or
tacrolimus- (without belatacept, termed tacrolimus alone) based regimens at hospital discharge
following transplant surgery after June 1st, 2011 and followed up through December 1st, 2014.
Recipients were excluded if they received other organ transplants or used cyclosporine as a
maintenance immunosuppressant drug at hospital discharge.

Outcomes
Patients were followed from the date of transplantation until death, graft loss (reported in

SRTR as return to dialysis or re-transplantation), loss to follow-up, or 1 year after the transplant date,
whichever came first. The primary outcomes for the study included: one-year composite patient
death or graft loss and one-year incidence of biopsy-proven acute rejection (BPAR). The secondary
outcomes included mean estimated glomerular filtration rate (eGFR) at 1 year using the modification
of diet in renal disease (MDRD) equation (mL/min/1.73m2) (12, 13), the one-year incidence of newonset diabetes after transplantation (NODAT), and the one-year incidence of post-transplant
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lymphoproliferative disease (PTLD) and other new-onset malignancy. Primary and secondary
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outcomes within 1 year were compared between belatacept+tacrolimus-, belatacept alone- and
tacrolimus alone-treated patients. Further analyses were conducted in the subgroups to investigate
the association of drug regimens and outcomes in specific patient populations.

Covariates
Recipient demographic and clinical characteristics, as well as donor characteristics, were

examined for the belatacept- and tacrolimus-treated groups. Recipient covariates in this study
included: age, race (black versus others), gender, BMI (obese defined as BMI ≥30 kg/m2 versus nonobese, BMI<30 kg/m2), pre-transplant cardiovascular disease, previous history of malignancy,
previous kidney transplant, steroid use at hospital discharge, mycophenolate use at hospital
discharge, cause of end stage renal disease (hypertension, diabetes, glomerulonephritis, polycystic
kidney disease, and other), recipient panel reactive antibody (PRA), pre-transplant dialysis duration
(>2 years, 0-2 years versus none), HLA mismatch (>3 versus ≤3), induction with lymphocytedepleting (LD) agents (antithymocyte globulin or alemtuzumab), recipient insurance (private versus
others), and recipient Epstein-Barr virus (EBV) serostatus (positive or negative). Donor characteristics
were: age, gender, race, and graft types (living donor, SCD, or ECD).

Center Effect
Belatacept use was not uniform in U.S. transplant centers. Only 25% of U.S. transplant

centers had begun to use belatacept prior to December 01, 2014. Fifty seven percent of KTR who
received belatacept by that date were transplanted at just one of the sixty U.S. centers using the
drug, which was named “major belatacept center”. Based on SRTR discharge immunosuppression
records, seventy five percent of the recipients who received belatacept at the major belatacept
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center were treated with a combined regimen of belatacept+tacrolimus. The other 59 transplant
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centers in this study, whose rate of belatacept use ranged from 0.1% to 15.8%, were grouped
together and named “other belatacept centers”. The risks associated with the major and other
belatacept center types was defined as a co-variate “center effect” for the purpose of adjustments in
the multivariable models.

Subgroup Analysis
Subgroup analyses were performed to investigate the associations of different induction

drugs (LD or non-LD) as part of each immunosuppression regimen with the clinical outcomes related
to belatacept use. Multivariate analyses were performed for the two primary outcomes in the entire
study cohort, as well as for the two different induction groups. To compare the current study results
with those from the two major belatacept clinical trials, BENEFIT and BENEFIT-EXT, the primary
clinical outcomes were also analyzed in patients who met the same inclusion and had none of the
exclusion criteria specified in these trials. Specifically, those recipients meeting criteria for the
BENEFIT trial (living donor or SCD, with cold ischemia time < 24h and PRA < 50% for first transplants
and < 30% for re-transplants) were designated as BENEFIT-eligible recipients, while those recipients
meeting criteria for the BENEFIT-EXT trial (donors ≥60 years old; or donors ≥50 years old who had at
least two other risk factors of hypertension, death from cerebrovascular accident, or serum
creatinine >1.5mg/dL; or cold ischemia time of ≥24 hours; or donation after cardiovascular death)
were designated as BENEFIT-EXT-eligible recipients. High PRA KTR, defined as first-time transplants
with a PRA ≥50% or re-transplants with a PRA ≥30% (exclusion criteria for both BENEFIT and
BENEFIT-EXT trials) were also investigated.

This article is protected by copyright. All rights reserved.
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Statistical Analysis
Categorical variables were compared between the comparison groups using chi-square tests,

whereas continuous variables were compared using student t-tests for two-group comparison and F
test for more than two-group comparison. Multivariate Cox proportional hazards model was used to
assess the hazard ratio for the first occurrence of patient death or graft loss or BPAR within the first
post-transplant year comparing three different regimens. The assumption of proportional hazards
underlying the Cox model was tested and confirmed by visually inspecting the complementary loglog survival plots for the primary explanatory variables and by examining the Schoenfeld residual
plots. To fit the multivariate model, a univariate analysis was first conducted with the major
exposure variable and then with each covariate added one at a time to examine the change of the
estimate of the major exposure variable. The covariates that modified the estimate of the major
exposure variable over 3% were kept in the final multivariate model. All analyses were conducted
using SAS 9.4 (Cary, NC). The significance level was set at P<.05, unless multiple comparisons were
conducted.

Results
Patient characteristics

A total of 50 244 adult recipients underwent solitary kidney transplantation from June 1,
2011 through December 1, 2014. Based on immunosuppression reported at the time of
discharge, 875 KTR received a belatacept regimen (417 concomitantly with tacrolimus and
458 on belatacept alone). A total of 49 369 KTR received tacrolimus but not belatacept
(tacrolimus alone). At 12 months post-transplant, 54%, 57%, and 66% of patients in the
belatacept+tacrolimus, belatacept alone, and tacrolimus alone groups, respectively, had
reported post-transplant immunosuppressant information. Only 29%, 44%, and 63% of
This article is protected by copyright. All rights reserved.

patients in these groups maintained the discharge drug regimens at one-year follow up,
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respectively. Out of 417 belatacept+tacrolimus-treated patients at 1 year, 123 remained on
belatacept+tacrolimus at 12 months, 71 were treated with belatacept alone, 26 were
treated with tacrolimus alone, and 4 were switched to other immunosuppressants. None of
belatacept+tacrolimus-treated patients in “other belatacept centers” maintained the
discharge drug regimen at 12 months.
The demographic and clinical characteristics of the belatacept+tacrolimus-,

belatacept alone-, and tacrolimus alone-treated patients are compared in Table 1. Most of
the P values for the comparisons between cohorts appear significant due to the large
sample size. However, only the following factors achieved a clinically meaningful difference
of >10% between cohorts: induction drug use, EBV seropositivity, recipient PRA, recipient
race, steroid use and transplant center. Patients who received a belatacept+tacrolimus
regimen were more likely than belatacept-alone and tacrolimus-alone patients to have
received a transplant at the major belatacept center (90% vs 28% vs 0.43%, P<.0001,
respectively). Compared to belatacept alone-treated patients, belatacept+tacrolimustreated patients were also more likely to be sensitized (PRA higher than 20%: 37% vs 21%,
respectively; P<.0001), be African American (49% vs 23%, P<.0001), and be retransplants
(10% vs 5%, P=.0025), while less likely to have received LD induction drugs (7% vs 51%,
P<.0001). Thus, aside from being discharged more often on steroids (92% vs 77%, P<.0001),
the patients who received the belatacept+tacrolimus regimen had overall more baseline
factors considered to increase the risk for acute rejection.

This article is protected by copyright. All rights reserved.
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Patient/graft survival

All patient and graft survival outcomes data are listed in Table 2. The rates of

one-year patient death, death with functioning graft, death-censored graft loss, and
composite patient death or graft loss in the two belatacept (belatacept+tacrolimus
and belatacept alone) regimens were not significantly different than those of the
tacrolimus alone group.

Acute rejection
Figure 1a compares the unadjusted one-year BPAR rates of the overall study

population, BENEFIT-eligible recipients, and BENEFIT-EXT-eligible recipients. The
rates of one-year BPAR were numerically similar between belatacept+tacrolimusand belatacept alone-treated KTR in the overall study population (16.8% vs 18.8%,
P=.44), BENEFIT-eligible patients (15.7% vs 16.7%, P=.75), and BENEFIT-EXTeligible patients (17.1% vs 19.1%, P=.71). However, these rejection rates (in the
belatacept+tacrolimus- and belatacept alone-treated KTR) were significantly higher
than those in the tacrolimus alone-treated KTR across the three comparison groups
(6.5% in all patients, 6.0% in BENEFIT-eligible, 6.6% in BENEFIT-EXT-eligible
patients).
Figure 1b compares the one-year BPAR rates between treatment groups

under LD and non-LD induction regimens. The use of LD induction drugs was
associated with lower one-year BPAR rates in the KTR who received belataceptalone (14.6% vs 23.1%, P=.02), with no significant difference observed in
belatacept+tacrolimus recipients (20.7% vs 16.5%, P=.56). Subgroup analysis in
belatacept-alone treated KTR meeting BENEFIT-EXT criteria demonstrated a high
rejection rate in those receiving non-LD induction (27.1%) compared to those
This article is protected by copyright. All rights reserved.

receiving LD induction (11.9%, P=.03). The lowest rejection rates were observed in
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the tacrolimus-alone group with either induction agent (6.2% in LD induction, and
7.1% in non-LD induction).
High PRA recipients, who were excluded from the BENEFIT and BENEFIT-EXT clinical trials,

experienced more one-year BPAR in the two belatacept groups than in the tacrolimus alone group
(19.7% vs 36.4% vs 8.3% for belatacept+tacrolimus, belatacept alone, and tacrolimus alone,
respectively, P<.0001). The highest rate of one-year BPAR occurred in the belatacept alone-treated
high PRA patients who received non-LD induction (43%).

Table 3 contains the adjusted hazard ratios for BPAR within one year of

transplantation with belatacept+tacrolimus vs tacrolimus alone treatments, and
belatacept alone vs tacrolimus alone treatments, and belatacept+tacrolimus vs
belatacept alone treatments. Compared with tacrolimus alone, a significantly
increased risk of BPAR associated with belatacept alone use within the first year was
identified in the overall study cohort (aHR: 2.36; 95%CI: 1.82-3.05, P<.0001),
BENEFIT-eligible recipients (aHR: 2.51, 95%CI: 1.79-3.52, P<.0001), BENEFITEXT-eligible recipients (aHR: 1.74, 95%CI: 1.06-2.85, P<.03), recipients who
received LD induction (aHR: 1.86; 95%CI: 1.20-2.90, P=.006), and recipients who
received non-LD induction (aHR: 2.65; 95%CI: 1.90-3.70, P<.0001). Compared with
tacrolimus alone, belatacept+tacrolimus treatment was not significantly associated
with an increased risk of BPAR within 1 year in the overall study cohort or subgroup
analyses, although the BPAR risk was suggestively higher in recipients who received
LD induction (aHR: 2.35; 95%CI: 0.94 – 5.90, P=.07). Furthermore, in All Recipients
and Recipients Used Non LD Induction, the risk of rejection was lower with
belatacept + tacrolimus treatment compared to belatacept alone, and was
suggestively lower in BENEFIT-eligible Recipients and BENEFIT-EXT-eligible
This article is protected by copyright. All rights reserved.

Recipients. Only in the Recipients Used LD Induction Drugs group did there not
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appear to be a benefit of adding tacrolimus of belatacept. Multivariate analysis could
not be performed on the high PRA group due to insufficient patient numbers.

Renal function
Figure 2 shows the comparison of eGFR at 1 year between the three drug regimens for all

recipients, BENEFIT-eligible recipients, and BENEFIT-EXT-eligible recipients. The eGFR was
significantly higher in the belatacept+tacrolimus and belatacept alone-treated recipients than in the
tacrolimus alone-treated recipients in all recipients (64.1 vs 63.5 vs 58.6 mL/min/1.73m2,
respectively, P=.0015) and in the BENEFIT-EXT-eligible group (65.6 vs 60.4 vs 54.3 mL/min/1.73m2,
respectively, P=.0003), although no significant differences were seen in the BENEFIT-eligible
recipients (62.6 vs 63 vs 60 mL/min/1.73m2, respectively, P=.13). There were no significant
differences in eGFR between belatacept+tacrolimus and belatacept alone patients in all subgroups.

New onset diabetes and malignancy
Figure 3 compares the incidences of NODAT, de novo PTLD, and other new

onset malignancy between the three-drug regimens for all recipients based on data
at 1 year post-transplant follow up. The incidence of NODAT was significantly lower
in the belatacept+tacrolimus and belatacept alone groups than in the tacrolimus
alone group (1.7% vs 2.2% vs 3.8%, respectively, P=.01). The incidences of de novo
PTLD or other new onset malignancy were similar in the three comparison groups.
None of the belatacept-treated patients who developed PTLD were EBV
seronegative or received LD induction therapy.

This article is protected by copyright. All rights reserved.
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In the current study, the absolute rates of one-year BPAR in belatacept alonetreated patients were similar to those reported in the two clinical trials (16.7% and
18.6% in BENEFIT-eligible and BENEFIT-EXT-eligible, respectively, compared to
17% and 17.7% for the BENEFIT and BENEFIT-EXT trials, respectively), although
the belatacept alone-treated patients had significantly higher BPAR rates compared
to the tacrolimus alone-treated recipients in all study groups. Furthermore, in
belatacept alone-treated recipients treated with a non-LD induction drug, the
absolute one-year BPAR rate was higher at 23.1%. Treatment with a non-LD
induction drug but addition of tacrolimus to the belatacept regimen
(belatacept+tacrolimus-treated recipients) at discharge reduced the one-year BPAR
rejection rate down to 16.5%. The belatacept+tacrolimus-treated patients who
received LD induction were at higher risk for rejection than belatacept alone-treated
patients, which likely explains this group having the highest absolute rejection rate in
all recipients receiving LD induction (20.7%). Indeed, multivariate analysis
demonstrated no significant difference in hazard ratios for rejection between
belatacept+tacrolimus and tacrolimus alone patients with LD induction and in all
groups studied. However, BPAR rates in the belatacept+tacrolimus-treated patients
who received LD induction are suggestively higher than in those treated with
tacrolimus alone, although the group comprised only 29 patients. Further
investigation with larger sample size is clearly needed to be able to draw any further
conclusions. In the real clinical setting, there are often high PRA patients, who were
excluded from the clinical trials. In fact, the highest absolute rate of rejection was
observed in the high PRA patients who did not receive LD induction (43%). Taken in
sum, the data regarding rejection in this study would suggest caution with the use of

This article is protected by copyright. All rights reserved.
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for the first year post-transplant, especially in recipients with a high baseline risk for
rejection.
At 12 months, renal function was superior in patients receiving belatacept versus

cyclosporine in both the BENEFIT and BENEFIT-EXT trials (9, 10). In the current study, renal function
was no different between belatacept+tacrolimus, belatacept alone-, and tacrolimus-treated patients
at 12 months in the patients meeting BENEFIT criteria. However, in those patients meeting BENEFITEXT criteria, renal function was significantly greater in belatacept+tacrolimus- and belatacept aloneversus tacrolimus alone-treated patients. In patients meeting BENEFIT or BENEFIT-EXT criteria, renal
function in the tacrolimus alone-treated patients (60 and 54 mL/min/1.73M2, respectively) was
observed to be numerically higher than that reported for the cyclosporine-treated patients in the
BENEFIT and BENEFIT-EXT trials (50 and 45 mL/min/1.73M2, respectively).
In both the BENEFIT and BENEFIT-EXT trials, belatacept was associated with significant

improvement in cardiometabolic complications of blood pressure and lipid control compared to
cyclosporine, and in the BENEFIT-EXT trial, a significant reduction in incidence of NODAT was also
reported. In the current study, only the incidence of NODAT could be assessed, since the SRTR
database does not contain measurements for blood pressure or lipid levels. In both belatacepttreated groups, the one-year incidence of NODAT was significantly lower in comparison to
tacrolimus alone-treated patients. It therefore does not appear that tacrolimus as used in the
belatacept+tacrolimus group incurs the same risk for NODAT as with the standard usage of the drug,
which along with the eGFR results, leads one to speculate that the combined regimen involved lower
goal tacrolimus levels, especially since steroid use was significantly higher in this group.
In the BENEFIT and BENEFIT-EXT trials, 1.0% of patients receiving the approved dosage

developed PTLD during the first year compared to 0.2% of those who received cyclosporine, with
most of the cases in EBV seronegative patients. In the current study, only 0.22% of belatacept-
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treated (>94% EBV seropositive) versus 0.13% of tacrolimus alone-treated patients developed PTLD
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in this same time frame, which may reflect greater awareness among clinicians of the role EBV
seropositivity plays in the proper selection of belatacept candidates to decrease this risk. A total of 9
other new onset malignancies occurred during one-year follow up in belatacept+tacrolimus (0.5%)
and belatacept alone groups (1.5%), which were not statistically different with the tacrolimus alone
group (1.2%).
The major strength of this study is the large study population available through use of the

nationwide SRTR dataset, which enhances generalizability of the study findings and provides the
power for precision of the statistical analyses. The limitations of this study include missing posttransplant follow up data for the primary outcomes and the lack of data on important secondary
outcomes, such as blood pressure, lipid panel measurements, and infection diagnoses. The
immunosuppressant drug dosage and trough levels are not collected by the SRTR, and similarly, the
types of acute rejection cannot be ascertained. Information is also lacking on the presence of donor
specific antibodies and whether protocol or for cause biopsies were performed at each individual
center.

Conclusion
Despite a higher rate of acute rejection, belatacept alone use was associated with non-

inferior effects on composite patient death or one-year graft loss outcome compared with
tacrolimus alone use in a real clinical setting. The acute rejection rates were particularly high in
those recipients with high PRA who did not receive LD induction. Belatacept use resulted in
significantly higher renal function at 1 year compared to tacrolimus in BENEFIT-EXT eligible
recipients of kidneys from marginal donors. It is unknown at this time whether the superior graft
function at 1 year will translate into better long-term graft survival in this cohort. Finally a
significantly lower incidence of NODAT was observed with belatacept use, even when combined with
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tacrolimus during parts of the first year. It may be advisable to add short-term tacrolimus to
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belatacept during the first year post-transplant and consider LD induction in all but the lowest risk
patients, as the risk to benefit ratio allows.

Acknowledgments
This work was supported by the Gatorade Trust through funds distributed by the University

of Florida, Division of Nephrology, Hypertension, and Renal Transplantation, and the Central Florida
Kidney Center, Inc. Eminent Scholar Chair in Nephrology and Hypertension.

Disclaimer
The data reported here have been supplied by the Minneapolis Medical Research

Foundation as the contractor for the SRTR. The interpretation and reporting of these data are the
responsibility of the author(s) and in no way should be seen as an official policy of or interpretation
by the SRTR or the United States Government.

Disclosure
The authors of this manuscript have no conflicts of interest to disclose as described by the American
Journal of Transplantation.

This article is protected by copyright. All rights reserved.

Figure Legends

Accepted Article

Figure 1. (A) Comparison of unadjusted one-year BPAR rates between three drug regimens in All
Recipients, BENEFIT-eligible Recipients, and BENEFIT-EXT-eligible Recipients. The rates of one-year
BPAR were numerically similar between belatacept+tacrolimus- and belatacept alone- treated KTR in
the overall study population, BENEFIT-eligible patients, and BENEFIT-EXT-eligible patients. However,
these rejection rates (in the belatacept+tacrolimus- and belatacept alone-treated KTR) were
significantly higher than those in the tacrolimus alone-treated KTR across the three comparison
groups. BPAR, biopsy-proven acute rejection; KTR, kidney transplant recipients. (B) Comparison of
one-year unadjusted BPAR rates between three drug regimens in patients receiving lymphocytedepleting and non lymphocyte-depleting induction. The use of lymphocyte depleting induction drugs
was associated with lower one-year BPAR rates in the recipients who received belatacept-alone,
whereas these rates were higher in belatacept+tacrolimus recipients. The lowest rejection rates
were observed in the tacrolimus-alone group with either induction agent. BPAR, biopsy-proven
acute rejection; KTR, kidney transplant recipients.

Figure 2. Comparison of eGFR at 1 year between three drug regimens in All Recipients, BENEFITeligible Recipients, and BENEFIT-EXT-eligible Recipients. The eGFR was significantly higher in the
belatacept+tacrolimus or belatacept alone-treated recipients than in the tacrolimus alone-treated
recipients in all recipients and in the BENEFIT-EXT-eligible group, although no significant differences
were seen in the BENEFIT-eligible recipients. There were no significant differences in eGFR between
belatacept+tacrolimus and belatacept alone in either subgroup. KTR, kidney transplant recipients;
eGFR, estimated glomerular filtration rate.

Figure 3. Comparison of metabolic and malignancy outcomes at 1 year
between three drug regimens. The incidence of NODAT was significantly lower in
the two belatacept groups than in the tacrolimus-alone group. The incidences of de
novo PTLD or other new onset malignancy were similar in the three comparison
groups. KTR, kidney transplant recipients; NODAT, new onset diabetes after
transplantation; PTLD, post-transplant lymphoproliferative disease; KTR, kidney
transplant recipients.
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Table 1. Demographic and clinical characteristics of study populations
Characteristics
Belatacept- Belatacept
Tacrolimus
and
AloneAloneTacrolimusTreated
Treated
Treated
KTR
KTR
KTR
N=458
N=49 369
N=417
Recipient Age, Years, Mean ± SD 51.5 ± 13.1 53.7 ± 13.9 51.9 ± 13.6
Recipient African American Race,
N (%)
204 (49)
105 (23)
12 283 (25)
Recipient Female Gender, N (%)
174 (42)
155 (34)
19 091 (39)
Dialysis Length Pre-transplant, N
(%)
55 (13)
90 (20)
9185 (19)
Preemptive
90 (22)
138 (30)
14 334 (29)
0-2 Years
272 (65)
230 (50)
25 850 (52)
> 2 Years
Recipient BMI>30, N (%)
128 (31)
163 (36)
16906 (34)
Cause of ESRD, N (%)
Hypertension
99 (24)
107 (23)
10 987 (22)
Diabetes
112 (27)
124 (27)
12 980 (26)
This article is protected by copyright. All rights reserved.

P
Value

.017
<.000
1
.05
<.000
1

.0017
.04

Glomerulonephritis
Polycystic Kidney Disease
Other
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Donor Age, Years, Mean ± SD
Donor Female Gender, N (%)
Donor African American Race, N (%)

110 (26)
35 (8)
61 (15)
39.0 ± 15.6

95 (21)
54 (12)
78 (17)
43.6 ± 14.6

10 661 (22)
4792 (10)
9949 (20)
39.5 ± 14.9

227 (54)
118 (28)

236 (52)
67 (15)

23 192 (47)
6605 (13)

143 (34)
238 (57)
36 (9)

186 (41)
208 (45)
64 (14)

16 408 (33)
28 096 (57)
4865 (10)

Donor Type by OPTN, N (%)
Living Donor
Standard Criteria Donor
OPTN Extended Criteria Donor*
Donor Type by BENEFIT Trials Criteria**,
N (%)
BENEFIT-eligible Donors
BENEFIT-EXT-eligible Donors
High PRA Recipients
Donor Death Due to Cerebrovascular
Accident, N (%)
Donor Hypertension, N (%)
Donor Diabetes, N (%)
Recipient PRA, N (%)
0~20
20~50
50~80
≥80
Recipient Epstein-Barr Virus
Seropositivity, N (%)
HLA Mismatch >3, N (%)

<.000
1
.0016
<.000
1
<.000
1

<.000
1
236 (57)
105 (25)
76 (18)
49 (18)

299 (65)
126 (28)
33 (7.2)
43 (16)

29 253 (59)
13 310 (27)
6806 (14)
4709 (14)

91 (22)
154 (37)

107 (23)
205 (45)

10 031 (20)
19 003 (38)

247 (62)
60 (15)
37 (9)
56 (14)
410 (98)

319 (78)
49 (12)
15 (4)
25 (6)
431 (94)

30 827 (68)
5 402 (12)
3 861 (9)
5 030 (11)
38 011 (77)

286 (69)

293 (64)

32 008 (65)

Cold Ischemia Time, Hours,
Mean ± SD
Delayed Graft Function, N (%)
Induction with LD Agents, N (%)

11.4 ± 8.8

12.1 ± 10.0

12.4 ± 10.3

82 (20)
29 (7)

91 (20)
233 (51)

8554 (17)
33 228 (67)

Steroid Use at Discharge, N (%)

384 (92)

354 (77)

34 633 (70)

Mycophenolate Mofetil Use at
Discharge, N (%)
Sirolimus Use at Discharge, N
(%)
Recipient with Cardiovascular
Disease, N (%)
Recipient Previous Malignancy, N
(%)
Recipient Primary Insurance,
Private, N (%)
Recipients with Previous Kidney
Transplant, N (%)

411 (99)

423 (92)

47 963 (97)

0 (0)

22 (4.8)

470 (1)

44 (11)

56 (12)

4578 (9)

<.000
1
.02

35 (8)

50 (11)

3452 (7)

.003

110 (26)

170 (37)

17 476 (35)

42 (10)

23 (5)

5931 (12)

<.000
1
<.000
1
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.19
.21
.02
<.000
1

<.000
1
<.000
1
.09
.17
<.000
1
<.000
1
<.001
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Recipient Physical Capacity with
Limitation, N (%)
Recipient Serum Creatinine at
Discharge, Mean ± SD

385 (92)

402 (88)

39 969 (81)

3.1 ± 2.6

3.2 ± 3.0

2.9 ± 2.6

377 (90)

126 (28)

214 (43)

8.7 ± 7.0

10 ± 9

12.9 ± 10.2

2 (0.5)
126 (30.2)
159 (38.1)
130 (31.2)

62 (13.5)
109 (23.8)
132 (28.8)
155 (33.8)

8716 (17.7)
14 234
(28.8)
14 744
(29.9)
11 675
(23.7)

Kidney Transplant Center, N (%)
Major Belatacept Center
Mean Follow Up (Months),
Mean ± SD
Year of Transplant, N (%)***
2011
2012
2013
2014

<.000
1
.01

<.000
1
<.000
1
<.000
1

*: OPTN Extended Criteria Donor, defined as donors ≥60 years old; or donors ≥50
years old and who had at least two other risk factors (hypertension, death from
cerebrovascular accident, or serum creatinine >1.5mg/dL).
**: (i) BENEFIT-eligible Donor, defined as living donors and non extended criteria
deceased donors with cold ischemia time of <24 hours. Excluded were donation
after cardiac death deceased donors, first-time transplants with a PRA ≥50%, and
re-transplants with a PRA ≥30%.
(ii) BENEFIT-EXT-eligible Donor, defined as donors ≥60 years old; or donors ≥50
years old and who had at least two other risk factors (hypertension, death from
cerebrovascular accident, or serum creatinine >1.5mg/dL); or cold ischemia time
of ≥24 hours; or donation after cardiovascular death.
(iii) High PRA Recipients are first-time patients with a panel reactive antibody
≥50% or re-transplants with a panel reactive antibody ≥30%.
***: Column percent adds to 100%.
KTR, kidney transplant recipients; SD, standard deviation; BMI, body mass index;
ESRD, end stage renal disease; PRA, panel reactive antibody; HLA, human
leukocyte antigen; LD, lymphocyte-depleting; OPTN, Organ Procurement and
Transplantation Network.
Table 2: Patient/Graft Survival in All Recipients, BENEFIT-eligible Recipients, BENEFIT-EXT-eligible
Recipients, and High PRA Recipients.
Patient
Groups

Month 12 Endpoints

All
Recipients

Number of Patients
Graft Loss or Death, N (%)
Death Censored Graft Loss
Death
Death with Functioning Graft

Belatacept+
Tacrolimus
N (%)
N=417

Belatacept
Alone
N (%)
N=458

Tacrolimus
Alone
N (%)
N=49 369

13 (3.1)
6 (1.4)
9 (2.2)
7 (1.7)

17 (3.7)
7 (1.5)
12 (2.6)
10 (2.2)

2002 (4.1)
1067 (2.2)
1154 (2.3)
982 (2.0)
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Recipients*
BENEFITEXT- eligible
Recipients*
*
High PRA
Recipients*
**

Number of Patients
Graft Loss or Death, N (%)
Death Censored Graft Loss
Death
Death with Functioning Graft
Number of Patients

N=236

N=299

N=29 253

7 (3)
3 (1.3)
4 (1.7)
4 (1.7)

10 (3.3)
4 (1.3)
7 (2.3)
6 (2.0)

894 (3.1)
453 (1.6)
530 (1.8)
466 (1.6)

N=105

N=126

N=13 310

Graft Loss or Death, N (%)
Death Censored Graft loss
Death
Death with Functioning graft
Number of Patients
Graft Loss or Death, N (%)
Death Censored Graft Loss
Death
Death with Functioning Graft

4 (3.8)
2 (1.9)
3 (2.9)
2 (1.9)

6 (4.8)
2 (1.6)
5 (4.0)
4 (3.2)

842 (6.3)
463 (3.5)
486 (3.7)
396 (3.0)

N=76

N=33

N=6806

2 (2.6)
1 (1.3)
2 (2.6)
1 (1.3)

1 (3.0)
1 (3.0)
0 (0.0)
0 (0)

266 (3.9)
151 (2.2)
138 (2.0)
120 (1.8)

* BENEFIT-eligible Donor, defined as living donors and non extended criteria
deceased donors with cold ischemia time of <24 hours. Excluded were donation
after cardiac death deceased donors, first-time transplants with a PRA ≥50%, and
re-transplants with a PRA ≥30%.

**BENEFIT-EXT-eligible Donor, defined as donors ≥60 years old; or donors ≥50 years
old and who had at least two other risk factors (hypertension, death from
cerebrovascular accident, or serum creatinine >1.5mg/dL); or cold ischemia time of
≥24 hours; or donation after cardiovascular death
***High PRA Recipients are first-time patients with a panel reactive antibody ≥50% or
re-transplants with a panel reactive antibody ≥30%
PRA, panel reactive antibody.
Table 3. Adjusted hazard ratios for one-year BPAR
Outcomes

Groups

Adjusted Hazard Ratio (95% CI, P value)
Belatacept+Tacro
limus vs
Tacrolimus Alone

Belatacept
Alone vs
Tacrolimus
Alone
One-Year
All Recipients
1.33
2.36
Biopsy
(0.93 – 1.90,
(1.82 – 3.05,
Proven
P=.12)
P<.0001)
Acute
Recipients Used
2.35
1.86
Rejection
Lymphocyte- Depleting
(0.94 – 5.90,
(1.20 – 2.90,
Induction Drugs
P=.07)
P=.006)
Recipients Used Non
1.39
2.65
Lymphocyte- Depleting
(0.93 – 2.08,
(1.90 – 3.70,
Induction Drugs
P=.11)
P<.0001)
BENEFIT-eligible Recipients
1.65
2.51
(0.98 – 2.78,
(1.79 – 3.52,
P=.06)
P<.0001)
BENEFIT-EXT-eligible
0.73
1.74
Recipients
(0.38 – 1.40,
(1.06 – 2.85,
P=.35)
P=.027)
Critical P value is .017 due to Bonferroni adjustment for multiple comparisons.
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Belatacept+Tacrol
imus vs
Belatacept Alone
0.54
(0.36 – 0.81,
P=0.003)
1.50
(0.51 – 4.41,
P=0.47)
0.50
(0.32 – 0.76,
P=0.001)
0.64
(0.35 – 1.15,
P=0.13)
0.41
(0.18 – 0.96,
P=0.04)
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Other covariates adjusted in the model include: recipient age, race, gender, steroid use at hospital
discharge, mycophenolate mofetil use at hospital discharge, panel reactive antibody, pre-transplant
dialysis duration, HLA mismatch, recipient insurance, and recipient Epstein-Barr virus infection.
Donor characteristics were: donor age, and donor types.
Induction with lymphocyte-depleting agents was only adjusted in the multivariate model for All
Recipients, BENEFIT-eligible Recipients, and BENEFIT-EXT-eligible recipients. For the subgroup
analyses in Patients used Lymphocyte-Depleting Induction Drugs or Recipients Used Non
Lymphocyte-Depleting Induction Drugs, choice of induction agent was not adjusted in the
multivariate model.

BPAR, biopsy proven acute rejection; CI, confidence interval.

Figure 1. a) Comparison of unadjusted one-year BPAR rates between three drug regimens in All
Recipients, BENEFIT-eligible Recipients, and BENEFIT-EXT-eligible Recipients. The rates of one-year
BPAR were numerically similar between belatacept+tacrolimus- and belatacept alone- treated KTR in
the overall study population, BENEFIT-eligible patients, and BENEFIT-EXT-eligible patients. However,
these rejection rates (in the belatacept+tacrolimus- and belatacept alone-treated KTR) were
significantly higher than those in the tacrolimus alone-treated KTR across the three comparison
groups. BPAR, biopsy-proven acute rejection; KTR, kidney transplant recipients.
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Figure 1. b) Comparison of one-year unadjusted BPAR rates between three drug regimens in
patients receiving lymphocyte-depleting and non lymphocyte-depleting induction. The use of
lymphocyte depleting induction drugs was associated with lower one-year BPAR rates in the
recipients who received belatacept-alone, whereas these rates were higher in belatacept+tacrolimus
recipients. The lowest rejection rates were observed in the tacrolimus-alone group with either
induction agent. BPAR, biopsy-proven acute rejection; KTR, kidney transplant recipients.

Figure 2. Comparison of eGFR at 1 year between three drug regimens in All Recipients, BENEFITeligible Recipients, and BENEFIT-EXT-eligible Recipients. The eGFR was significantly higher in the
belatacept+tacrolimus or belatacept alone-treated recipients than in the tacrolimus alone-treated
recipients in all recipients and in the BENEFIT-EXT-eligible group, although no significant differences
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were seen in the BENEFIT-eligible recipients. There were no significant differences in eGFR between
belatacept+tacrolimus and belatacept alone in either subgroup. KTR, kidney transplant recipients;
eGFR, estimated glomerular filtration rate.

Figure 3. Comparison of metabolic and malignancy outcomes at 1 year between three drug
regimens. The incidence of NODAT was significantly lower in the two belatacept groups than in the
tacrolimus-alone group. The incidences of de novo PTLD or other new onset malignancy were similar
in the three comparison groups. KTR, kidney transplant recipients; NODAT, new onset diabetes after
transplantation; PTLD, post-transplant lymphoproliferative disease; KTR, kidney transplant
recipients.
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